This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Page, S. T. Articles by Bremner, W. J. Search for Related Content PubMed PubMed Citation Articles by Page, S. T. Articles by Bremner, W. J.

Testosterone Administration Suppresses Adiponectin Levels in Men

KAREN L. HERBST

BRADLEY D. ANAWALT^*,

ALVIN M. MATSUMOTO^*,,

From the ^* Department of Medicine, Veterans Affairs-Puget Sound Health Care System, and Geriatric Research Education and Clinical Center, University of Washington School of Medicine, Seattle, Washington; and the Department of Medicine, Charles Drew University, University of California at Los Angeles School of Medicine, Los Angeles, California.

Correspondence to: Stephanie T. Page, University of Washington Medical Center, Division of Endocrinology and Metabolism, 1959 NE Pacific, Box 357138, Seattle, WA 98195 (e-mail: page{at}u.washington.edu).

Testosterone (T) administration to men increases lean body mass and decreases fat mass. Adiponectin is produced by adipocytes and is thought to influence insulin sensitivity. In this study, we sought to determine whether experimental alterations in serum T change adiponectin levels in normal men. We measured adiponectin levels in 28 healthy men ages 18-35 years before and during treatment with a potent gonadotropin-releasing-hormone (GnRH) antagonist, acyline. Decreased T levels led to increased serum adiponectin within 7 days; maximal adiponectin levels were reached on day 21 (baseline 8.6 ± 0.9 compared with 12.2 ± 1.0 µg/mL on day 21, P < .05) and persisted through day 30, despite no significant changes in body mass index (BMI) and an increase in leptin. The addition of T to acyline, maintaining serum T levels within the normal range, prevented the increase in adiponectin following acyline alone. In a second study, 25 men aged 55-85 years were treated with 3 weeks of high-dose T (testosterone enanthate [TE], 600 mg/wk intramuscularly). With high serum T levels, adiponectin levels decreased significantly by day 21 of treatment (baseline 14.3 ± 1.9 compared with 10.8 ± 1.5 µg/mL, P < .05 vs baseline and placebo), BMI slightly increased, and leptin levels were decreased. We conclude that adiponectin levels increase within days of experimental T deficiency in normal men, and the increase in adiponectin is prevented by T replacement. Furthermore, supraphysiologic T administration results in decreased adiponectin levels. Our data support the hypothesis that T, its metabolites, or both directly suppress adipocyte production of adiponectin.

     Key words: Androgen, hypogonadal, leptin

This article has been cited by other articles:

				A. A. Yassin and F. Saad Testosterone and Erectile Dysfunction J Androl, November 1, 2008; 29(6): 593 - 604. [Abstract] [Full Text] [PDF]

				E. Resmini, G. Andraghetti, A. Rebora, R. Cordera, L. Vera, M. Giusti, F. Minuto, and D. Ferone Leptin, Ghrelin, and Adiponectin Evaluation in Transsexual Subjects During Hormonal Treatments J Androl, September 1, 2008; 29(5): 580 - 585. [Abstract] [Full Text] [PDF]

				M. J. Toth, B. C. Cooper, R. E. Pratley, A. Mari, D. E. Matthews, and P. R. Casson Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1035 - E1045. [Abstract] [Full Text] [PDF]

				E. Corpeleijn, E. J.M. Feskens, E. H.J.M. Jansen, M. Mensink, W. H.M. Saris, and E. E. Blaak Lifestyle Intervention and Adipokine Levels in Subjects at High Risk for Type 2 Diabetes: The Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM) Diabetes Care, December 1, 2007; 30(12): 3125 - 3127. [Abstract] [Full Text] [PDF]

				R. B. S. Harris, T. J. Bartness, and H. J. Grill Leptin Responsiveness in Chronically Decerebrate Rats Endocrinology, October 1, 2007; 148(10): 4623 - 4633. [Abstract] [Full Text] [PDF]

				D. Barb, C. J Williams, A. K Neuwirth, and C. S Mantzoros Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence Am. J. Clinical Nutrition, September 1, 2007; 86(3): 858S - 866S. [Abstract] [Full Text] [PDF]

				D. Glintborg, M. Andersen, C. Hagen, J. Frystyk, V. Hulstrom, A. Flyvbjerg, and A. P. Hermann Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur. J. Endocrinol., August 1, 2006; 155(2): 337 - 345. [Abstract] [Full Text] [PDF]

				M.-H. Gannage-Yared, S. Khalife, M. Semaan, F. Fares, S. Jambart, and G. Halaby Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur. J. Endocrinol., July 1, 2006; 155(1): 167 - 176. [Abstract] [Full Text] [PDF]

				A. Bojesen, K. Kristensen, N. H. Birkebaek, J. Fedder, L. Mosekilde, P. Bennett, P. Laurberg, J. Frystyk, A. Flyvbjerg, J. S. Christiansen, et al. The Metabolic Syndrome Is Frequent in Klinefelter's Syndrome and Is Associated With Abdominal Obesity and Hypogonadism Diabetes Care, July 1, 2006; 29(7): 1591 - 1598. [Abstract] [Full Text] [PDF]

				M Mitchell, D T Armstrong, R L Robker, and R J Norman Adipokines: implications for female fertility and obesity Reproduction, November 1, 2005; 130(5): 583 - 597. [Abstract] [Full Text] [PDF]